Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 102Cyclophosphamide 74fludarabine 45Idarubicin 39Decitabine 36Etoposide 35Azacitidine 34Methotrexate 31Daunorubicin 30Vincristine 28Dexamethasone 27venetoclax 25Busulfan 24Imatinib Mesylate 23Radiotherapy 20Mercaptopurine 20Granulocyte Colony-Stimulating Factor 20Dasatinib 19Peripheral Blood Stem Cell Transplantation 18Mitoxantrone 17Doxorubicin 17Immunotherapy, Adoptive 16Rituximab 15Asparaginase 15Tretinoin 14Cladribine 14fludarabine phosphate 13Prednisone 13Prednisolone 13Melphalan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × bisantrene × Other hematologic neoplasm × Clear all
NCT04989335 2023-11-28

Bisantrene Combination for Resistant AML

Sheba Medical Center

Phase 2 Unknown
29 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡